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Introduction
The analysis of the health dynamics status among Ukrainian population in recent years shows a negative trend, namely the deterioration of life quality and patients life expectancy [1, 2] . An indisputable leader in this process is coronary artery disease (CAD) and especially its acute forms, which are associated with high mortality [3, 4] . On this basis, the study of different aspects of this problem is of great interest for the practical health care of Ukraine.
Among the acute forms of CAD, NSTEMI is associated with extremely unanticipated course and unfavorable prognosis in the near and distant period [4] . Therefore, the development of NSTEMI stratification and prognosis is in the focus of scientific society. In this sense, various non-invasive biomarkers, such as troponin I (TnI), natriuretic peptide (BNP and NT-proBNP), galectin-3, growth factor-expressing gene 2 (ST2) and others, have been recently studied in detail [5] . Among the latter, a great deal of attention is paid to ST2 [6] .
ST2 as a neurohumoral factor attracted attention due to already available scientific data on its unique properties and a fairly wide range of pathophysiological effects and a potential role in the diagnosis and prognosis of asymptomatic and symptomatic structural remodelling and fibrosis of myocardium and myocardial dysfunction [7, 8] . The diagnostic value of the biomarker has been demonstrated in both acute coronary syndromes and chronic stable heart failure [9, 10] . ST2 has proven to be a highly informative marker in predicting left ventricular remodeling and monitoring positive treatment response in patients with systolic heart failure (HF), exceeding the sensitivity of factors such as NT-proBNP, highly sensitive cardiac troponin T and galectin-3 [11, 12] .
Thus, the modern scientific sources analysis demonstrates the prospect of using ST2 level in plasma as a diagnostic marker that reflects the presence and severity of structural remodelling of myocardium in various cardiovascular pathologies, including MI [13, 14] .
The aim of the study was to evaluate ST2 level in plasma among the patients with NSTEMI and its relationship according to different clinical characteristics.
Materials and methods
All studies conform to the principles of the Declaration of Helsinki of the World Medical Association. The study protocol, the form of informed consent of patients and other documents related to the study were approved at the meeting of the Academic Council of the National Pirogov Memorial Medical University, Vinnytsya (excerpt from the protocol No. 2 from 28.11.2017). Informed consent to participate in the study was discussed and signed by all study participants.
The study is based on the results of a comprehensive examination of 165 patients aged 35 to 79 (average 60.7±0.8) years with various forms of CAD with and without arterial hypertension (HTN). Among the surveyed 114 (69.1 %) patients were male and 51 (30.9 %) were female respectively. The ratio of men to women was 2.2 to 1.0, indicating a significant predominance in the study of male patients (p<0.0001).
At the time of their inclusion in the study, all patients were hospitalized in the cardiology department for infarction patients of the Vinnytsya Regional Clinical Medical Diagnostic Center for Cardiovascular Pathology for 2016-2018 years.
The criteria for patient inclusion in the study were: different forms of CAD (NSTEMI, STEMI, NSTE-ACS, chronic coronary syndromes) and patients age from 30 to 80 years. The exclusion criteria were:
1) past and repeated acute myocardial infarction; 2) the age of patients under 30 and over 80;
3) HF NYHA III-IV at the time of the study inclusion; 4) diseases of the respiratory system, kidneys and liver, which were accompanied by signs of pulmonary, renal and hepatic failure; anemic conditions with haemoglobin levels below 110 g/l; 5) presence of rheumatic and congenital heart defects, idiopathic and inflammatory myocardial lesions; 6) malignancies, severe neuropsychiatric disorders, alcohol abuse. The main clinical trial was presented to 90 patients with NSTEMI aged 38 to 79 (mean 61.3±1.1) years. Among them, 60 (66.7 %) patients were male and 30 (33.3 %) were female respectively. The ratio of men to women was 2.0 to 1.0 (p<0.0001). It was noted that in the main clinical group, as well as in the general cohort of patients, men predominated significantly. Time from the moment of destabilization to hospitalization in the hospital ranged from 1 to 24 and averaged 10.6±1.0 hours. In the vast majority (87.8 %) of patients with NSTEMI according to the ECG recorded anterior localization of MI (in 87.8 % -depression of ST-segment from 2 to 5 mm and in 12.2 % -T-wave inversion from 2 to 6 mm in two or more leads) and an increase in plasma troponin levels compared to the reference rate of 2.5 to 18.4 ng/ml (7.5±0.5 ng/ml on average).
As groups of comparison were formed 3 groups with other different clinical forms of CAD. Thus, group 1 consisted of 25 patients with verified chronic coronary syndromes (CCS) (mean age -60.6±2.4 years, men -68.0 % and women -32.0 % respectively); group 2 -25 patients with NSTE-ACS (mean age -61.4±2.4 years, males -68.0 % and females -32.0 %, respectively) and 3rd -25 patients with STEMI (mean age 58.3±2.3 years, males 80.0 % and females 20.0 %, respectively). In patients with STEMI, unlike the main group, there was a significantly shorter mean period from the destabilization onset to hospitalization (6.3 vs. 10.6 h, p<0.001) and the incidence of anterior MI localization (64.9 % vs. 87.8 %, p=0.006) and a higher mean troponin level (10.4 vs. 7.5 ng/ml, p=0.003) which was logical.
The majority of the surveyed had concomitant HTN, the incidence of which was 84. Laboratory study of the plasma ST2 levels was performed by enzyme-linked immunosorbent assay in all patients on the first day of hospitalization before hospital coronary and ventriculography (CVG). Presage® ST2 Assay EIA Test Kits No. BC-1065E and BC-1066E manufactured by CRITICAL DIAGNOSTICS 3030 Bunker Hill St. Suite 117A San Diego, CA 92109 were used to determine ST2.
The difference between the main clinical group and the comparison group, the gender difference and the difference of ST2 level depending on different clinical characteristics were calculated using nonparametric statistical methods (Mann-Whitney test). The statistical significance of the difference between the measured parameters among the CAD groups was calculated by Kruskal-Wallis ANOVA & Median test.
Results
The results of the present investigation were that the ST2 level in the main cohort was in range from 5.5 to 233.9 (in the middle -49.8±3.5 ng/ml (median indicator -34.7 and the inter-quartile range -21.9 and 59.1 respectively). Tables 1-2 show indicators of statistics, which characterize the variability of ST2 level in small groups of illnesses.
Noteworthy significantly higher ST2 level in patients with NSTEMI, unlike the comparison group, in the analysis of medians (35.9 vs. 27.7 ng/ml, p=0.047) and no statistical differences in the mean values. The latter index clearly argues, in the case of high variability of indicators in groups, the need to use nonparametric methods of comparison (the table compares the median of the indicator according to Mann-Whitney U test). Mann-Whitney U test: р=0.047
Note: NSTEMI -non-ST elevation myocardial infarction In turn, the comparison of ST2 levels in patients with various forms of CAD ( Table 2 ) showed significant differences between groups with acute MI (1 and 3 groups) and patients with NSTE-ACS and CCS (2 and 4 groups) -35.9 and 36.1 against 24.1 and 23.4 ng/ml, p<0.05 in the absence of significant differences between patients with different types of MI (35.9 and 36.1 ng/ml, p=1.00). Therefore, it should be thought that a significantly higher level of ST2 is present in patients with acute MI, regardless of its variant compared with patients with CCS and NSTE-ACS.
The results of ST2 analysis in the main clinical group in gender and age ( Table 3 ) did not show significant differences in biomarker's levels in women and men (p=0.38), as well as patients of different age criteria (p=0.94). Table 4 ) showed significant higher hormone levels in patients with concomitant HTN (39.9 vs. 31.2 ng/ml, p=0.04) and type 2 diabetes (68.5 vs. 35.5 ng/ml, p=0.04), in the presence of such a risk factor as smoking (39.6 vs. 32.7 ng/ml, p=0.03) and impaired cardiovascular heredity (41.8 vs. 32.6 ng/ml, p=0.01). Therefore, based on the data obtained, it should be noted that in patients with NSTEMI, the ST2 level in plasma, in a certain way, depends on the presence of concomitant diseases such as HTN and type 2 diabetes, risk factors such as smoking and impaired hereditary cardiovascular pathology. The highest ST2 level was observed in patients with concomitant type 2 diabetes mellitus (68.5 ng/ml). The latter confirms the already known fact that type 2 diabetes is considered to be the most powerful factor in the development of myocardial dysfunction and HF in patients with MI. In turn, analysis of ST2 level depending on MI nature ( Table 5 ) showed that a significantly higher level of neurohormone was determined at anterior localization of MI according to the ECG (37.9 vs. 29.4 ng/ml, p=0.03), in the case of high risk on the GRACE scale (≥140 points) (42. In addition, the analysis showed a significantly higher ST2 level in patients with NSTEMI in the presence of acute cardiac arrhythmias (47.1 vs 35.6 ng/ml, p=0.004) and acute HF (Killip III) (56.3 vs 35,2 ng/ml, p=0.02) during hospitalization of patients.
Thus, in patients with NSTEMI, a certain association of ST2 level in plasma with the MI course was detected. A higher level of neurohormone is registered with anterior unlike posterior ECG localization of MI; at high unlike moderate risk on the GRACE scale; when complicated unlike the uncomplicated course of MI; in the case of acute HF and cardiac arrhythmias unlike patients with the absence of these manifestations in the acute period of MI.
Discussion
The results obtained in the course of our study indicated a correlation of ST2 level with different clinical and instrumental characteristics. Thus, an increased level of biomarker was determined in patients with myocardial infarction compared with the control group, which is confirmed by the literature [15, 16] . The rate was higher in the group of patients with concomitant hypertension, hereditary history, smoking, diabetes and obesity. Most of the literature is centred around STEMI, while ST2 is not well understood in NSTEMI [9, 17] .
We investigated ST2 levels depending on the localization of myocardial infarction and its complications, which obtained conclusive data regarding the increase of the level of biomarker in the main group compared with the control group.
Given that ST2 levels are correlated with the risk of an unfavourable course of myocardial infarction, its determination in the early stages of the disease allows for appropriate correction of treatment, such as dose modification of drugs or changes in their combinations. If relevant clinical data are available with regard to STEMI, there is very little data regarding NSTEMI [18] .
Study limitations. This study examines the therapeutic aspects of the ratio of ST2 levels and the clinical-instrumental characteristics of NSTEMI, while the surgical aspects are forced to be neglected. However, the data obtained during the study confirm the indisputable relationship between the level of biomarker and the character of the course of CAD and concomitant HF [19, 20] .
Prospects for further research. Of great interest are the associations of ST2 level with the character of the anatomic lesions of the coronary arteries, in particular, the correlative connections according to the SYNTAX score, but we attribute this research to further and prospective studies. The following data will help to optimize the tactics of treating patients in the early period of myocardial infarction immediately after emergency coronary angiography and angioplasty.
Conclusions
1. High variability of ST2 level in plasma was demonstrated in patients with NSTEMI on the first day after destabilization (minimum and maximum values -12.7 and 233.9 respectively, median -35.9 and interquartile range -25.9 and 55.7 ng/ml).
2. It is shown that significantly higher ST2 level in plasma is determined in patients with acute MI regardless of its variant among different clinical forms of CAD.
3. It is found that significantly higher level of ST2 in patients with NSTEMI is recorded in the case of concomitant HTN and type 2 diabetes, with smoking and heavy cardiovascular heredity. Proved influence of the character of MI course on the level of ST2 in plasma, significantly higher level of neurohormone was determined with anterior localization of MI, high risk on the GRACE scale (≥ 140 points), complicated course of MI, development of cardiac arrhythmias and HF in the acute period of MI.
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